Data gathered: November 27
Alternative Data for ORIC Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 5 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 5,000 | Sign up | Sign up | Sign up |
| Google Trends | 6 | Sign up | Sign up | Sign up |
| Patents | 39 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 569 | Sign up | Sign up | Sign up |
| Twitter Followers | 467 | Sign up | Sign up | Sign up |
| Twitter Mentions | 11 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 115 | Sign up | Sign up | Sign up |
About ORIC Pharmaceuticals
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States.
| Price | $9.97 |
| Target Price | Sign up |
| Volume | 166,610 |
| Market Cap | $696M |
| Year Range | $6.63 - $14.59 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
ORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesNovember 25 - Yahoo |
 |
FY2024 EPS Forecast for ORIC Pharmaceuticals Cut by AnalystNovember 19 - ETF Daily News |
|
Wedbush Lowers Earnings Estimates for ORIC PharmaceuticalsNovember 16 - ETF Daily News |
|
ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational UpdatesNovember 12 - Yahoo |
 |
HC Wainwright Reiterates Buy Rating for ORIC Pharmaceuticals (NASDAQ:ORIC)November 8 - ETF Daily News |
|
ORIC® Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)November 1 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 7.1M | -7.1M | -35M | 0 | -0.490 |
| Q2 '24 | 0 | 7.1M | -7.1M | -32M | -36M | -0.450 |
| Q1 '24 | 0 | 7M | -7M | -25M | -29M | -0.370 |
| Q4 '23 | 1.5M | 6.9M | -6.9M | -28M | -31M | -0.490 |
| Q3 '23 | 0 | 6.3M | -6.3M | -25M | -29M | -0.440 |
Insider Transactions View All
| Chacko Jacob filed to sell 728,544 shares at $16.2. March 8 '24 |
| Chacko Jacob filed to sell 794,586 shares at $12.1. February 8 '24 |
| Piscitelli Dominic filed to sell 83,809 shares at $8.6. December 19 '23 |
| Multani Pratik S filed to sell 23,809 shares at $8.6. December 19 '23 |
| Chacko Jacob filed to sell 808,544 shares at $8.6. December 19 '23 |
Similar companies
Read more about ORIC Pharmaceuticals (ORIC) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews & linkedin employees.
What is the Market Cap of ORIC Pharmaceuticals?
The Market Cap of ORIC Pharmaceuticals is $696M.
What is the current stock price of ORIC Pharmaceuticals?
Currently, the price of one share of ORIC Pharmaceuticals stock is $9.97.
How can I analyze the ORIC stock price chart for investment decisions?
The ORIC stock price chart above provides a comprehensive visual representation of ORIC Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling ORIC Pharmaceuticals shares. Our platform offers an up-to-date ORIC stock price chart, along with technical data analysis and alternative data insights.
Does ORIC offer dividends to its shareholders?
As of our latest update, ORIC Pharmaceuticals (ORIC) does not offer dividends to its shareholders. Investors interested in ORIC Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of ORIC Pharmaceuticals?
Some of the similar stocks of ORIC Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.